BIRMINGHAM, Ala. June 23, 2011 /PRNewswire/ -- Centrix Pharmaceutical, Inc., a privately-held specialty pharmaceutical company focused on Pediatrics and Women's Health, announces a promotional agreement with CutisPharma, Inc., a Woburn, Massachusetts based company. The partnership will include the promotion of FIRST® - Progesterone VGS, vaginal suppository compounding kits.
Beginning early July, 2011, Centrix Pharmaceutical sales representatives will promote FIRST® - Progesterone VGS compounding kits from CutisPharma, Inc. in physician offices, clinics, and hospitals who specialize in obstetrics and gynecology in addition to retail pharmacies nationwide.
About FIRST® - Progesterone VGS compounding kit
The product line includes FIRST® - Progesterone VGS 25, 50, 100, 200, and 400. The kits are made for one patient and include pre-weighed progesterone, and suppository base, and a unique, patented disposable suppository mold for preparation, dispensing, and storage of the suppositories, all in one unit that increases patient compliance, and ease of use.
FIRST® - Progesterone VGS saves dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST® VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared in the conventional way using a metal suppository mold or polystyrene shells. A single NDC number assigned for the entire kit facilitates the third party reimbursement process, and reduces audit-related adjustments.
About Centrix Pharmaceutical, Inc.
Centrix Pharmaceutical is a privately-held specialty pharmaceutical company focused in Pediatrics and Women's Health. Headquartered in Birmingham, AL, the Company's products are marketed by its dedicated sales force in the United States. For more information about Centrix Pharmaceutical, Inc. visit www.cenrx.com.
About CutisPharma, Inc.
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending. For more information about CutisPharma, Inc., visit www.cutispharma.com.
|SOURCE Centrix Pharmaceutical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved